Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Urachal Mucinous Cystadenocarcinoma.
Pereira R, McGeorge S, Perera M, Vela I. Pereira R, et al. Among authors: vela i. BMJ Case Rep. 2019 Jan 22;12(1):e228089. doi: 10.1136/bcr-2018-228089. BMJ Case Rep. 2019. PMID: 30674499 Free PMC article.
Prostate cancer biomarkers: Are we hitting the mark?
McGrath S, Christidis D, Perera M, Hong SK, Manning T, Vela I, Lawrentschuk N. McGrath S, et al. Among authors: vela i. Prostate Int. 2016 Dec;4(4):130-135. doi: 10.1016/j.prnil.2016.07.002. Epub 2016 Jul 29. Prostate Int. 2016. PMID: 27995111 Free PMC article. Review.
Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, Christidis D, Bolton D, Hofman MS, Lawrentschuk N, Murphy DG. Perera M, et al. Among authors: vela i. Eur Urol. 2020 Apr;77(4):403-417. doi: 10.1016/j.eururo.2019.01.049. Epub 2019 Feb 14. Eur Urol. 2020. PMID: 30773328
The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial.
Joshi A, Roberts MJ, Perera M, Williams E, Rhee H, Pryor D, Lehman M, Heathcote P, Wood S, Coucher J, Gustafson S, Miles K, Vela I. Joshi A, et al. Among authors: vela i. Clin Exp Metastasis. 2020 Aug;37(4):551-560. doi: 10.1007/s10585-020-10043-1. Epub 2020 Jun 9. Clin Exp Metastasis. 2020. PMID: 32519046 Clinical Trial.
Open retropubic radical prostatectomy.
Pereira R, Joshi A, Roberts M, Yaxley J, Vela I. Pereira R, et al. Among authors: vela i. Transl Androl Urol. 2020 Dec;9(6):3025-3035. doi: 10.21037/tau.2019.09.15. Transl Androl Urol. 2020. PMID: 33457276 Free PMC article. Review.
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG; proPSMA Study Group Collaborators. Hofman MS, et al. Among authors: vela i. Lancet. 2020 Apr 11;395(10231):1208-1216. doi: 10.1016/S0140-6736(20)30314-7. Epub 2020 Mar 22. Lancet. 2020. PMID: 32209449 Clinical Trial.
57 results